Stubborn inflation data has the Federal Reserve anticipating only two rate cuts in 2025. That’s why investors are watching the November PCE report closely, given that it is the Fed’s preferred inflation gauge. One of the biggest movers is Novo Nordisk. The company released a study that showed its experimental obesity drug helped patients lose weight, but not as much as hoped. Other trending tickers include Nike, FedEx, and Eli Lilly. Key guests include: 9:05 a.m. ET – Victoria Fernandez, Crossmark Global Investments Chief Market Strategist 10:00 a.m. ET – John Stoltzfus, Oppenheimer & Co. Chief Investment Strategist 10:15 a.m. ET – Yung-Yu Ma, BMO Wealth Management, U.S. Chief Investment Officer 10:30 a.m. ET – Isaac Stone Fish, Strategy Risks Founder and CEO 11:10 a.m. ET – Andrew Kadjeski, Vanguard Head of Brokerage & Investments